Becton, Dickinson and Company (BDX)

Over the past six months, BDX's stock price has been influenced by several events. Q2 FY25 earnings led to a stock dip due to sales falling short of estimates and a contraction in gross margin. At the Goldman Sachs conference, Becton Dickinson presented its strategic plans. The announcement of a deal to combine its biosciences and diagnostic business with Waters Corp caused a stock drop. Q3 FY25 earnings positively impacted the stock due to strong results and raised EPS guidance. At the Wells Fargo conference, Becton Dickinson provided updates on its strategic focus and plans for share buybacks.

Becton, Dickinson & Co.'s worldwide sales are generally not seasonal. However, certain medical devices within the BD Medical segment and respiratory and flu diagnostic products in the BD Diagnostics segment experience seasonality due to their relation to seasonal diseases like influenza.

Becton, Dickinson & Co. (BDX), also known as BD, is a global medical technology company that manufactures and sells medical devices, instrument systems, reagents, and provides consulting and analytics services. The company operates in three segments: BD Medical, which includes products like syringes, needles, and diabetes management tools; BD Life Sciences, which offers integrated diagnostic solutions and instruments for clinical diagnostics and cell analysis; and BD Interventional, which provides devices for vascular access, surgical instruments, and infection prevention products.

BDX has a significant global presence, operating in over 190 countries and employing more than 75,000 people. International markets contribute substantially to the company's revenue. The United States remains a stable growth market for BD. The company has manufacturing operations in numerous countries, including the U.S., Brazil, Canada, France, Germany, Hungary, India, Japan, Mexico, and Bosnia and Herzegovina.

In the past year, Becton, Dickinson & Co. has received positive recognitions, contributing to a strong brand reputation. The company was named to TIME's list of the World's Best Companies and recognized among the 100 Best Corporate Citizens of 2024 by 3BL. BD Medication Management Technology was ranked Best in KLAS for Automated Dispensing Cabinets and Traditional Smart Pumps for the sixth consecutive year. The company was also named to Fortune's list of America's Most Innovative Companies and recognized by the Business Group on Health for Excellence in Employee Well-Being. Additionally, it was named to USA TODAY's list of America's Climate Leaders.

Becton, Dickinson & Co. has a diverse ownership structure. Institutional investors hold a significant majority of the company's stock. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., T. Rowe Price Investment Management, Inc., and State Street Corp. Insiders own a small percentage of the stock, while retail investors hold a minority stake.